Thursday, October 15, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· May 14, 2026

POET Technologies Reports First Quarter 2026 Financial Results

View original at globenewswire.com
“The Company reported a net loss of $12.3 million, or ($0.08) per share, in the first quarter of 2026”
Verbatim excerpt from the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • POET's Optical Interposer-based products are lower cost, consume less power than comparable products, are smaller in size and are readily scalable to high production volumes

    60% confidence
  • In Q1 2026, POET made significant progress expanding its strategic position within the AI and hyperscale data center ecosystem; partnerships with LITEON, Lessengers and Lumilens validate growing demand for POET's Optical Interposer platform

    60% confidence
  • POET continued to advance its product roadmap through joint development of a 1.6T transceiver platform with Lessengers, strengthened global position through LITEON collaboration, and plans US domicile as demand for AI networking infrastructure accelerates

    60% confidence
  • The largest component of Q1 2025 net income was a non-cash gain in fair value adjustment to derivative warrant liability of $15.4 million, compared to a gain of $1.6 million in Q1 2026

    60% confidence
  • The Lumilens purchase order represents the first phase of a broader supplier relationship that could scale to $500+ million in cumulative purchases over five years

    60% confidence
  • Fluctuations in R&D expense for a company of POET's size and stage of growth is expected on a period-over-period basis as the Company transitions from technology development to product development

    60% confidence
  • The Lumilens joint development agreement including the initial $50M purchase order for EOI-based optical engines represents an important commercial milestone and could become a substantial long-term supplier relationship supporting frontier AI infrastructure

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com